Synthetic analog · 6 amino acids · 1,047.2 Da

Pasireotide studies and research data

PepBank has 76 pasireotide studies with results. All of them gave pasireotide, with 517 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 517 results and 484 papers. Newer studies from Europe PMC

Results in people

418

81% of 517 results

Results in animals

4% of 517 results

Results in lab cells

15% of 517 results

From computer models

0% of 517 results

The molecule

Pasireotide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Pasireotide is a cyclic six-residue somatostatin analog. Short-acting and depot formulations have different approved indications and regimens.

Kind: Synthetic analog · 6 residues
Identifiers: ChEMBLCHEMBL3349607 (opens in a new tab)PubChem CID9941444 (opens in a new tab)UNII98H1T17066 (opens in a new tab)DrugBankDB06663 (opens in a new tab)CAS396091-73-9
Parent: Analog of SomatostatinPasireotide is a synthetic somatostatin analog. P61278 identifies the human somatostatin precursor, not pasireotide. No contiguous parent sequence mapping is assigned.
Development: Approved in the US and EU (Signifor)An approved medicinal product exists. Availability and other indications can differ. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Somatostatin receptors	Agonist	Official prescribing information, mechanism of actionSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

6 amino acids · 4 modifications

Parent: Somatostatin

No sequence is listed for the parent, so no alignment is shown.Pasireotide is a synthetic somatostatin analog. P61278 identifies the human somatostatin precursor, not pasireotide. No contiguous parent sequence mapping is assigned.

Properties

From identity sources

Formula: C₅₈H₆₆N₁₀O₉
Molecular weight: 1,047.2 g/mol
Monoisotopic mass: 1,046.5014 Da

GSRS UNII 98H1T17066(opens in a new tab)retrieved 2026-10-27
PubChem CID 9941444(opens in a new tab)retrieved 2026-10-27
Curated Signifor US label(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Average mass: Not calculated
Monoisotopic mass: Not calculated
Isoelectric point (pI): Not calculated
Net charge at pH 7.4: Not calculated
GRAVY (hydropathy): Not calculated
Extinction coefficient, 280 nm (Cys reduced): 6,990 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index: Not calculated
Aliphatic index: Not calculated
Boman index: Not calculated
Hydrophobic moment (μH): Not calculated

2 non-canonical residues (X) are not included in calculated values.
The N-terminal group is not modeled.
The C-terminal group is not modeled.
D-amino acids have the same mass and charge as L forms. Hydrophobicity scales were measured on L forms.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Composition

Aromatic50% (3)F W Y
Positive17% (1)K
Non-canonical33% (2)X

6 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%

I Ile0 · 0%

L Leu0 · 0%

M Met0 · 0%

V Val0 · 0%

F Phe1 · 17%

W Trp1 · 17%

Y Tyr1 · 17%

H His0 · 0%

K Lys1 · 17%

R Arg0 · 0%

D Asp0 · 0%

E Glu0 · 0%

N Asn0 · 0%

Q Gln0 · 0%

S Ser0 · 0%

T Thr0 · 0%

C Cys0 · 0%

G Gly0 · 0%

P Pro0 · 0%

X Xaa2 · 33%

3D structure

PredictedAlphaFold DB · P61278

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 9941444(opens in a new tab)

C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN

Results by area

Pasireotide results by year and outcome

Counts are exact and come from studies that gave the peptide.

Pasireotide has 484 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

Studies by year

76 of 484 studies have results (16%), published 2006 to 2024. Top row: every study. Bottom row: studies with results about Pasireotide, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies484 in all, 2005 to 2026

Studies with results76 in all, 2006 to 2024

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Pasireotide studies on side effects

118 results · people 118 · animals 0 · lab 0

Top 5 of 118 results

In uncontrolled acromegaly, diarrhea occurred in 16% with pasireotide 40 mg versus 5% with continued octreotide or lanreotide.The lancet. Diabetes & endocrinology, 2014
In mastectomy and axillary dissection patients, overall safety was comparable between pasireotide and placebo.PloS one, 2016
In these patients, high blood sugar occurred more often with pasireotide than placebo.Clinical journal of the American Society of Nephrology, 2020
In uncontrolled acromegaly, high blood sugar occurred in 33% with pasireotide 40 mg versus 14% with continued octreotide or lanreotide.The lancet. Diabetes & endocrinology, 2014
In advanced lung or thymic carcinoids, 10% receiving pasireotide alone experienced suspected treatment-related grade 3-4 increases in a liver enzyme.The Lancet. Oncology, 2017

Pasireotide studies on blood sugar

56 results · people 50 · animals 6 · lab 0

Top 5 of 56 results

In postoperative dumping syndrome, pasireotide increased the lowest glucose level compared with placebo.Neurogastroenterology and motility, 2014
In Cushing's disease, drug-related high blood glucose occurred in 38.9% receiving pasireotide through the 24-month cut-off.Pituitary, 2015
In healthy men, pasireotide 600 μg was linked to higher blood sugar before meals than placebo.Endocrine, 2012
In acromegaly, fasting blood glucose increased from baseline during pasireotide LAR treatment.Journal of clinical pharmacology, 2014
In dumping syndrome patients receiving pasireotide, 26 of 43 had no low blood sugar during testing at month three.Alimentary pharmacology & therapeutics, 2018

Pasireotide studies on blood levels and clearance

48 results · people 48 · animals 0 · lab 0

Top 3 of 48 results

In healthy volunteers, pasireotide CAM4071 released faster initially than pasireotide LAR.Endocrine, 2024
In acromegaly, pasireotide LAR reached steady blood concentrations after three monthly injections.Journal of clinical pharmacology, 2014
In healthy men, pasireotide LAR released over one month with two concentration peaks.European journal of endocrinology, 2012

Pasireotide studies on cancer

58 results · people 43 · animals 2 · lab 13

Top 5 of 58 results

In advanced lung or thymic carcinoids, month 9 disease control was 39.0% with pasireotide versus 33.3% with everolimus.The Lancet. Oncology, 2017
In Cushing's disease, tumor shrinkage at month 6 occurred more frequently with pasireotide 900 μg than 600 μg twice daily.Pituitary, 2020
In corticotropinoma cells, the response to pasireotide was limited.The Journal of endocrinology, 2016
In refractory carcinoid tumors, progression-free survival was longer with pasireotide than octreotide.Drug design, development and therapy, 2015
In acromegaly, 39% of pasireotide-treated patients had a pituitary tumor volume reduction greater than 20%.The Journal of clinical endocrinology and metabolism, 2010

Pasireotide studies on hormones

36 results · people 34 · animals 0 · lab 2

Top 5 of 36 results

In Cushing's disease patients with elevated baseline saliva cortisol receiving pasireotide, 37.3% had normal saliva cortisol at month 6.Endocrine, 2016
During pasireotide treatment, normal urinary cortisol occurred in 13/81 patients at month 36 versus 42/81 at extension baseline.Clinical endocrinology, 2019
In cells from human pancreatic tumors, pasireotide reduced chromogranin A secretion at least as efficiently as octreotide.Endocrine-related cancer, 2014
In cells from human corticotroph adenomas, pasireotide reduced ACTH secretion in five of six tumors.The Journal of clinical endocrinology and metabolism, 2006
Among Cushing's disease extension entrants, 50.0% had controlled urinary cortisol at month 12 with pasireotide.Pituitary, 2015

Pasireotide studies on growth hormone and growth

35 results · people 29 · animals 0 · lab 6

Top 3 of 35 results

In acromegaly, pasireotide LAR achieved biochemical control more often than octreotide LAR.The Journal of clinical endocrinology and metabolism, 2014
In uncontrolled acromegaly, 15% achieved biochemical control with pasireotide 40 mg versus none with continued octreotide or lanreotide.The lancet. Diabetes & endocrinology, 2014
In healthy volunteers, pasireotide CAM4071 doses >5 mg reduced IGF-1 rapidly compared with pasireotide LAR.Endocrine, 2024

Pasireotide studies on overall treatment results

17 results · people 17 · animals 0 · lab 0

Top 5 of 17 results

In Cushing's disease, 17 pasireotide monotherapy patients achieved urinary cortisol control at week 35.Frontiers in endocrinology, 2023
In acromegaly, symptoms generally improved during pasireotide LAR treatment.Journal of clinical pharmacology, 2014
In Cushing's disease patients, clinical improvements persisted during pasireotide treatment.Clinical endocrinology, 2019
In pasireotide-treated Cushing's disease patients, joint cortisol control was linked to greater blood pressure and weight improvements than without joint control.European journal of endocrinology, 2020
In refractory carcinoid symptoms, control was numerically lower with pasireotide LAR than octreotide LAR, without a significant difference.Drug design, development and therapy, 2015

Pasireotide studies on daily life and fitness

15 results · people 15 · animals 0 · lab 0

Top 5 of 15 results

In pancreatectomy patients, quality-of-life measures showed no major differences between pasireotide and placebo.Annals of surgical oncology, 2016
In hepatic cyst patients, questionnaire scores improved in both groups, including placebo, and did not differ between pasireotide and placebo.European radiology, 2018
In Cushing's disease patients, psychosocial scores improved less than physical problem scores during pasireotide treatment.Journal of endocrinological investigation, 2020
In dumping syndrome patients, quality of life improved during subcutaneous pasireotide treatment and stayed improved during intramuscular treatment.Alimentary pharmacology & therapeutics, 2018
In Cushing's disease patients, quality of life improved from baseline during pasireotide treatment.Journal of endocrinological investigation, 2020

Pasireotide studies on receptors and cell signals

67 results · people 14 · animals 2 · lab 51

Top 5 of 67 results

In breast lesions, ER expression did not change after pasireotide.Breast cancer research, 2014
In patients with Cushing's disease, 17% achieved normal urinary cortisol after 15 days of pasireotide.The Journal of clinical endocrinology and metabolism, 2009
In healthy men, gallbladder volume after meals increased with pasireotide 200 and 600 μg.Endocrine, 2012
In healthy men, pasireotide results showed no dose dependency.The Journal of clinical endocrinology and metabolism, 2013
In cells, pasireotide triggered sst2 receptor entry less potently than octreotide.The Journal of clinical endocrinology and metabolism, 2009

Pasireotide studies on heart and blood vessels

10 results · people 10 · animals 0 · lab 0

Top 5 of 10 results

In postoperative dumping syndrome, pasireotide reduced the pulse rate increase compared with placebo.Neurogastroenterology and motility, 2014
In patients with controlled cortisol, systolic blood pressure decreased from baseline during pasireotide treatment.Journal of endocrinological investigation, 2020
In healthy volunteers, pasireotide 600 µg bid prolonged corrected QT by 13.2 milliseconds relative to placebo.Journal of clinical pharmacology, 2014
In Cushing's disease, blood pressure decreased during pasireotide treatment even without full urinary cortisol control.Clinical endocrinology, 2014
In dumping syndrome patients, pulse increases during glucose testing became less frequent than baseline after three months of pasireotide.Alimentary pharmacology & therapeutics, 2018

Pasireotide studies on survival and serious illness

7 results · people 6 · animals 1 · lab 0

Top 5 of 7 results

After partial pancreatectomy, one pasireotide patient and 2 hydrocortisone patients died within 30 days.JAMA surgery, 2020
In patients with metastatic NETs receiving pasireotide, survival at 30 months was 70%, and median survival was not reached.Endocrine-related cancer, 2015
In mice with bleomycin-induced fibrosis, pasireotide increased survival compared with saline.Thorax, 2008
After allogeneic HCT, one-year overall survival was lower with pasireotide than matched controls.PloS one, 2021
In advanced liver cancer patients receiving pasireotide, median survival was nine months.Journal of hepatocellular carcinoma, 2018

Pasireotide studies on use, access and costs

6 results · people 6 · animals 0 · lab 0

Top 4 of 6 results

In Cushing's disease patients, 39 of 81 completed the pasireotide extension.Clinical endocrinology, 2019
In pancreatic resection patients, mean cost was lower with pasireotide than placebo, but the difference was not statistically significant.Annals of surgery, 2017
In the pasireotide study, 33 of 43 patients completed the three-month subcutaneous phase.Alimentary pharmacology & therapeutics, 2018
In the Nelson's syndrome pasireotide study, four patients withdrew.Pituitary, 2018

Pasireotide studies on surgery and procedures

5 results · people 5 · animals 0 · lab 0

Top 4 of 5 results

After partial pancreatectomy, complication scores were lower with pasireotide than hydrocortisone, and hydrocortisone failed the noninferiority criterion.JAMA surgery, 2020
After mastectomy, the estimated share without symptomatic lymphoceles was 62.4% with pasireotide and 50.2% with placebo, a trend short of the 80% target.PloS one, 2016
After partial pancreatectomy, fistula occurred less frequently with pasireotide than hydrocortisone, without a significant difference.JAMA surgery, 2020
After distal pancreatectomy, pasireotide complication scores were 10.3 points lower than hydrocortisone scores.JAMA surgery, 2020

Pasireotide studies on liver

5 results · people 4 · animals 1 · lab 0

5 results

In severe polycystic liver disease, liver volume decreased with pasireotide and increased with placebo.Clinical journal of the American Society of Nephrology, 2020
In hepatic cyst patients receiving sclerotherapy, cyst reduction at six weeks was similar with pasireotide and placebo.European radiology, 2018
In advanced liver cancer patients receiving pasireotide, one patient had a reversible grade 4 rise in the liver enzymes ALT/AST.Journal of hepatocellular carcinoma, 2018
In hepatic cyst patients receiving sclerotherapy, long-term cyst reduction was similar with pasireotide and placebo.European radiology, 2018
In mice with polycystic kidney disease, pasireotide corrected liver enlargement.Journal of the American Society of Nephrology, 2015

Pasireotide studies on cholesterol and blood fats

4 results · people 4 · animals 0 · lab 0

Top 3 of 4 results

In Cushing's disease patients achieving urinary cortisol control, total cholesterol decreased during pasireotide treatment.Clinical endocrinology, 2014
In Chinese healthy men, pasireotide LAR substantially reduced triglycerides.Clinical therapeutics, 2014
In Cushing's disease patients achieving urinary cortisol control, LDL cholesterol decreased during pasireotide treatment.Clinical endocrinology, 2014

Pasireotide studies on stomach and gut

4 results · people 4 · animals 0 · lab 0

4 results

In postoperative dumping syndrome, pasireotide slowed stomach emptying of solids compared with placebo.Neurogastroenterology and motility, 2014
In patients with advanced NET and symptoms resistant to octreotide LAR, pasireotide controlled diarrhea and flushing in 27%.Endocrine-related cancer, 2012
After allogeneic HCT, pasireotide exposure was linked to less loss of microbial diversity than matched controls after adjustment.PloS one, 2021
In postoperative dumping syndrome, pasireotide slowed stomach emptying of liquids compared with placebo.Neurogastroenterology and motility, 2014

Pasireotide studies on blood and clotting

3 results · people 3 · animals 0 · lab 0

3 results

In patients with gastrointestinal bleeding, transfusion requirements were numerically lower with pasireotide than placebo.Therapeutic advances in gastroenterology, 2018
In patients with gastrointestinal bleeding, half of pasireotide recipients achieved the specified transfusion reduction from baseline.Therapeutic advances in gastroenterology, 2018
In patients with gastrointestinal bleeding, 83% of the pasireotide per-protocol group achieved the specified transfusion reduction from baseline.Therapeutic advances in gastroenterology, 2018

Pasireotide studies on weight and appetite

3 results · people 3 · animals 0 · lab 0

3 results

In Cushing's disease, weight, body mass index and waist circumference significantly decreased during pasireotide treatment.Journal of endocrinological investigation, 2020
In Cushing's disease, BMI, weight and waist size decreased during pasireotide treatment even without full urinary cortisol control.Clinical endocrinology, 2014
In Cushing's disease patients, body measurements improved during pasireotide treatment regardless of cortisol control.Journal of endocrinological investigation, 2020

Pasireotide studies on kidneys and bladder

4 results · people 2 · animals 2 · lab 0

Top 3 of 4 results

In these patients, kidney volume decreased with pasireotide and increased with placebo.Clinical journal of the American Society of Nephrology, 2020
In these patients, kidney filtration changes were similar with pasireotide and placebo.Clinical journal of the American Society of Nephrology, 2020
In mice with polycystic kidney disease, pasireotide alone reduced cyst progression.Journal of the American Society of Nephrology, 2015

Pasireotide studies on immune system and inflammation

5 results · people 2 · animals 1 · lab 2

5 results

After allogeneic HCT, acute GVHD was numerically higher with pasireotide than matched controls, without a significant difference.PloS one, 2021
In mice with bleomycin-induced fibrosis, pasireotide reduced lung inflammatory cell influx at day 3 compared with saline.Thorax, 2008
In lab tests, pasireotide decreased IL-6 release from pituitary tumour fibroblasts compared with before treatment.Endocrine-related cancer, 2019
After allogeneic HCT, chronic GVHD was numerically higher with pasireotide than matched controls, without a significant difference.PloS one, 2021
In lab tests, pasireotide decreased CCL2 release from pituitary tumour fibroblasts compared with before treatment.Endocrine-related cancer, 2019

Pasireotide studies on metabolism and nutrition

1 result · people 1 · animals 0 · lab 0

1 result

In Cushing's disease, visceral obesity, high cholesterol and high triglyceride prevalence decreased slightly during pasireotide treatment without statistical significance.Journal of endocrinological investigation, 2020

Pasireotide studies on lungs and breathing

9 results · people 0 · animals 6 · lab 3

Top 3 of 9 results

In mice with bleomycin-induced fibrosis, pasireotide reduced lung collagen at day 14 compared with saline.Thorax, 2008
In mice with bleomycin-induced fibrosis, pasireotide reduced lung collagen-1 mRNA at day 7 compared with saline.Thorax, 2008
In mice with bleomycin-induced fibrosis, pasireotide reduced lung connective tissue growth factor mRNA compared with saline.Thorax, 2008

Pasireotide studies on cells, genes and aging

1 result · people 0 · animals 0 · lab 1

1 result

In non-functioning pituitary adenoma cells, pasireotide increased cell viability.The Journal of endocrinology, 2016

Trials and papers

Pasireotide trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

76 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (25 of 76)

25 of 76 trials

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20102015202020252030

Ph 3
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
NCT00434148
Dec 2006 to May 2014
Ph 3
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
NCT00600886
11 Feb 2008 to 11 Mar 2016
Ph 3
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
NCT00690430
Apr 2008 to Apr 2012
Ph 3
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
NCT00994110
Oct 2009 to Sept 2014
Ph 2/3
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
NCT01620138
Mar 2010 to Jun 2012
Ph 3
PAOLA
NCT01137682
19 Jul 2010 to 28 Feb 2017
Ph 2
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
NCT01253161
1 Feb 2011 to 2 Mar 2023
Ph 2
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
NCT01313559
Jun 2011 to 29 Nov 2012
Terminated
Terminated
Ph 3
SEASCAPE
NCT01582061
16 Aug 2011 to 26 Jan 2017
Ph 3
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
NCT01374906
4 Nov 2011 to 21 Dec 2016

Browse all 76 matching trials in the list below

25 trials · 4 ongoing · 16 completed · 3 stopped early · 13 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01794793

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUPn = 33710 Jun 2013 to 25 Jul 2023

Cushing's Disease · Acromegaly · Neuroendocrine Tumors · Pituitary Tumors · Ectopic ACTH Secreting (EAS) Tumors · Dumping Syndrome · Prostate Cancer · Melanoma Negative for bRAF · Melanoma Negative for nRAS

Trial page ClinicalTrials.govUpdated 1 Oct 2024

WithdrawnPhase 4NCT02779257

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimoren = 0Apr 2016 to Jun 2016

Gastro-enteropancreatic Neuroendocrine Tumor

Trial page ClinicalTrials.govUpdated 4 Mar 2022

Active, not recruitingPhase 4NCT02775227

HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications

Helsinki University Central Hospitaln = 126May 2016 to est. Dec 2029

Pancreatic Fistula · Pancreatic Neoplasms

Trial page ClinicalTrials.govUpdated 24 Aug 2020

CompletedPhase 4Results postedNCT02060383

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Novartis Pharmaceuticalsn = 24923 May 2014 to 26 Mar 2018

Cushing's Disease · Acromegaly

Trial page ClinicalTrials.govUpdated 29 May 2019

Status unknownPhase 4NCT03514576

Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Zealand University Hospitaln = 51 Jun 2018 to est. 1 Nov 2018

Hypoglycemia, Reactive

Trial page ClinicalTrials.govUpdated 5 Jul 2018

CompletedPhase 4NCT02527993

Treatment of Hypoglycemia Following Gastric Bypass Surgery

Zealand University Hospitaln = 11Oct 2015 to 8 Apr 2017

Hypoglycemia · Obesity · Surgery

Trial page ClinicalTrials.govUpdated 7 Mar 2018

CompletedPhase 4NCT03080181

Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment

University of Palermon = 24May 2013 to 28 Jan 2017

Cushing Disease

Trial page ClinicalTrials.govUpdated 27 Oct 2017

Status unknownPhase 4NCT02668172

Pasireotide LAR and Pegvisomant Study in Acromegaly

Erasmus Medical Centern = 60Aug 2015 to est. Jun 2017

Acromegaly

Trial page ClinicalTrials.govUpdated 3 Aug 2016

CompletedPhase 3Results postedNCT02354508

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Novartis Pharmaceuticalsn = 12331 Mar 2015 to 27 Sept 2018

Acromegaly

Trial page ClinicalTrials.govUpdated 10 Dec 2019

CompletedPhase 3Results postedNCT01582061

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

Novartis Pharmaceuticalsn = 10416 Aug 2011 to 26 Jan 2017

Cushing's Disease

Trial page ClinicalTrials.govUpdated 19 Jun 2018

CompletedPhase 3Results postedNCT01374906

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Novartis Pharmaceuticalsn = 1504 Nov 2011 to 21 Dec 2016

Cushing's Disease

Trial page ClinicalTrials.govUpdated 22 May 2018

CompletedPhase 3Results postedNCT01137682

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Novartis Pharmaceuticalsn = 19819 Jul 2010 to 28 Feb 2017

Acromegaly

Trial page ClinicalTrials.govUpdated 5 Apr 2018

CompletedPhase 3Results postedNCT00600886

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Novartis Pharmaceuticalsn = 35811 Feb 2008 to 11 Mar 2016

Acromegaly

Trial page ClinicalTrials.govUpdated 2 Jul 2017

CompletedPhase 2/3Results postedNCT01620138

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Universidade Federal do Rio de Janeiron = 21Mar 2010 to Jun 2012

Non-functioning Pituitary Adenomas · Prolactinomas

Trial page ClinicalTrials.govUpdated 22 Aug 2016

CompletedPhase 3NCT02048319

Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts

Radboud University Medical Centern = 34Dec 2013 to Apr 2016

Symptomatic Dominant Liver Cyst

Trial page ClinicalTrials.govUpdated 4 May 2016

CompletedPhase 3Results postedNCT00434148

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

Novartis Pharmaceuticalsn = 162Dec 2006 to May 2014

Cushing's Disease

Trial page ClinicalTrials.govUpdated 8 Mar 2016

CompletedPhase 3Results postedNCT00994110

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Memorial Sloan Kettering Cancer Centern = 439Oct 2009 to Sept 2014

Pancreatic Cancer

Trial page ClinicalTrials.govUpdated 1 Feb 2016

CompletedPhase 3Results postedNCT00690430

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Novartis Pharmaceuticalsn = 186Apr 2008 to Apr 2012

Symptomatic Refractory Resistant Carcinoid Disease

Trial page ClinicalTrials.govUpdated 30 Jul 2013

Active, not recruitingPhase 2NCT05928390

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

RECORDATI GROUPn = 934 Jan 2024 to est. 29 Oct 2026

Post-Bariatric Hypoglycemia

Trial page ClinicalTrials.govUpdated 17 Sept 2026

RecruitingPhase 2NCT06295952

A Study of Pasireotide in People With Prolactinoma

Memorial Sloan Kettering Cancer Centern = 1027 Feb 2024 to est. Feb 2027

Prolactin-Producing Pituitary Tumor

Trial page ClinicalTrials.govUpdated 4 Mar 2026

CompletedPhase 2NCT02713776

Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment

Hospices Civils de Lyonn = 5713 Dec 2016 to 8 Jan 2021

Enterostomy

Trial page ClinicalTrials.govUpdated 19 Dec 2025

TerminatedPhase 2Results postedNCT01313559

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson Universityn = 6Jun 2011 to 29 Nov 2012

Castrate Resistant Prostate Cancer · Chemotherapy Naive Prostate Cancer · Prostate Cancer

Trial page ClinicalTrials.govUpdated 30 Apr 2025

RecruitingPhase 2NCT06456359

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

University Hospital Heidelbergn = 2819 Dec 2024 to est. Oct 2028

Desmoplastic Small Round Cell Tumor · Synovial Sarcoma

Trial page ClinicalTrials.govUpdated 13 Jan 2025

TerminatedPhase 2NCT04826432

Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Gustave Roussy, Cancer Campus, Grand Parisn = 63 Sept 2020 to 7 Feb 2024

Peritoneal Carcinomatosis

Trial page ClinicalTrials.govUpdated 8 Feb 2024

CompletedPhase 2Results postedNCT01253161

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

H. Lee Moffitt Cancer Center and Research Instituten = 291 Feb 2011 to 2 Mar 2023

Neuroendocrine Tumors · Carcinoid Tumors

Trial page ClinicalTrials.govUpdated 6 Mar 2023

7 more mention it but do not test it. They are not trials of Pasireotide: they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

484 studies match. Retracted studies are left out.

Showing 24 of 484 studiesquery qry_df48d269e5c1b1c3c5a03c48

Studies with results

76 studies in all, 17 on this page

Randomized controlled trial · 2014

10 results

Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.

Colao et al. 2014The Journal of clinical endocrinology and metabolismn = 358cited by 294

PMID 24423324PMC3965714DOI 10.1210/jc.2013-2480PUB-24423324

Free to read · publisher termsCC BY-NC5 results where Pasireotide was given

Read at source See results (10)

Randomized controlled trial · 2014

10 results

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

Gadelha et al. 2014The lancet. Diabetes & endocrinologyn = 133cited by 278

PMID 25260838DOI 10.1016/s2213-8587(14)70169-xPUB-25260838

Full text at the publisher10 results where Pasireotide was given

Publisher page See results (10)

Randomized controlled trial · 2013

11 results

Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.

Henry et al. 2013The Journal of clinical endocrinology and metabolismn = 45cited by 200

PMID 23733372DOI 10.1210/jc.2013-1771PUB-23733372

Full text at the publisher11 results where Pasireotide was given

Publisher page See results (11)

Non-randomized trial · 2009

6 results

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Boscaro et al. 2009The Journal of clinical endocrinology and metabolismn = 29cited by 183

PMID 18957506DOI 10.1210/jc.2008-1008PUB-18957506

Rights unknown6 results where Pasireotide was given

Source link See results (6)

Animal study (in vivo) · mouse · 2015

7 results

Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.

Duluc et al. 2015EMBO molecular medicinecited by 182

PMID 25834145PMC4459815DOI 10.15252/emmm.201404346PUB-25834145

CC BY7 results where Pasireotide was given

Download PDF See results (7)

Non-randomized trial · 2012

8 results

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

Kvols et al. 2012Endocrine-related cancern = 45cited by 143

PMID 22807497DOI 10.1530/erc-11-0367PUB-22807497

Rights unknown8 results where Pasireotide was given

Source link See results (8)

Randomized controlled trial · 2015

6 results

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.

Wolin et al. 2015Drug design, development and therapyn = 88cited by 143

PMID 26366058PMC4562767DOI 10.2147/dddt.s84177PUB-26366058

Free to read · publisher termsCC BY-NC6 results where Pasireotide was given

Read at source See results (6)

In vitro (cells) · 2006

2 results

The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.

Batista et al. 2006The Journal of clinical endocrinology and metabolismn = 6cited by 141

PMID 16940446DOI 10.1210/jc.2006-1245PUB-16940446

Full text at the publisher2 results where Pasireotide was given

Publisher page See results (2)

Non-randomized trial · 2010

4 results

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Petersenn et al. 2010The Journal of clinical endocrinology and metabolismcited by 138

PMID 20410233DOI 10.1210/jc.2009-2272PUB-20410233

Rights unknown4 results where Pasireotide was given

Source link See results (4)

In vitro (cells) · 2009

12 results

Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.

Lesche et al. 2009The Journal of clinical endocrinology and metabolismcited by 125

PMID 19001514DOI 10.1210/jc.2008-1919PUB-19001514

Full text at the publisher12 results where Pasireotide was given

Publisher page See results (12)

Randomized controlled trial · 2017

11 results

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

Ferolla et al. 2017The Lancet. Oncologyn = 83cited by 108

PMID 29074099DOI 10.1016/s1470-2045(17)30681-2PUB-29074099

Full text at the publisher11 results where Pasireotide was given

Publisher page See results (11)

Animal study (in vivo) · mouse · 2015

2 results

Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

Hopp et al. 2015Journal of the American Society of Nephrology : JASNcited by 101

PMID 24994926PMC4279738DOI 10.1681/asn.2013121312PUB-24994926

Rights unknown2 results where Pasireotide was given

Source link See results (2)

In vitro (cells) · 2007

6 results

Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Zatelli et al. 2007Endocrine-related cancercited by 96

PMID 17395978DOI 10.1677/erc-06-0026PUB-17395978

Full text at the publisher6 results where Pasireotide was given

Publisher page See results (6)

Animal study (in vivo) · rat and mouse · 2013

6 results

Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

Masyuk et al. 2013Hepatology (Baltimore, Md.)cited by 83

PMID 23172758PMC3616157DOI 10.1002/hep.26140PUB-23172758

Rights unknown5 results where Pasireotide was given

Source link See results (6)

Non-randomized trial · 2015

9 results

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Norden et al. 2015Neurologyn = 34cited by 83

PMID 25527270PMC4335993DOI 10.1212/wnl.0000000000001153PUB-25527270

Rights unknown9 results where Pasireotide was given

Source link See results (9)

In vitro (cells) · 2010

9 results

Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.

Pöll et al. 2010Molecular endocrinology (Baltimore, Md.)cited by 80

PMID 20051480PMC5428126DOI 10.1210/me.2009-0315PUB-20051480

Rights unknown7 results where Pasireotide was given (plus 1 on tools or combinations, listed separately)

Source link See results (9)

Non-randomized trial · 2014

5 results

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Pivonello et al. 2014Clinical endocrinologycited by 80

PMID 24533697DOI 10.1111/cen.12431PUB-24533697

Full text at the publisher5 results where Pasireotide was given

Publisher page See results (5)

More studies

404 studies in all, 7 on this page

PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase III · 2012

Corrected

A 12-month phase 3 study of pasireotide in Cushing's disease.

Colao et al. 2012The New England journal of medicinecited by 411

PMID 22397653DOI 10.1056/nejmoa1105743PUB-22397653

Full text at the publisher

Publisher page Read the notice

PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase III · 2014

Corrected

Pasireotide for postoperative pancreatic fistula.

Allen et al. 2014The New England journal of medicinecited by 297

PMID 24849084DOI 10.1056/nejmoa1313688PUB-24849084

Full text at the publisher

Publisher page Read the notice

PubMed tag: none · 2007

Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.

Taboada et al. 2007European journal of endocrinologycited by 156

PMID 17218727DOI 10.1530/eje.1.02313PUB-17218727

Rights unknown

Source link

PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase III · 2018

Corrected

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.

Lacroix et al. 2018The lancet. Diabetes & endocrinologycited by 127

PMID 29032078DOI 10.1016/s2213-8587(17)30326-1PUB-29032078

Full text at the publisher

Publisher page Read the notice

PubMed tag: none · 2020

Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention.

Hussman et al. 2020Frontiers in pharmacologycited by 122

PMID 32848776PMC7406916DOI 10.3389/fphar.2020.01169PUB-32848776

CC BY

Download PDF

PubMed tag: none · 2016

The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.

Hayashi et al. 2016European journal of endocrinologycited by 118

PMID 26578638DOI 10.1530/eje-15-0689PUB-26578638

Rights unknown

Source link

PubMed tag: none · 2016

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.

Iacovazzo et al. 2016European journal of endocrinologycited by 117

PMID 26586796DOI 10.1530/eje-15-0832PUB-26586796

Rights unknown

Source link

No result for Pasireotide (1 study on this page, 4 in all)

These studies name Pasireotide but give no result for it (for example, the results concern another peptide in the study).

Indexing hint: In vitro study · 2006

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.

Hubina et al. 2006European journal of endocrinologycited by 85

PMID 16868153DOI 10.1530/eje.1.02213PUB-16868153

Rights unknown

Source link

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Pasireotide studies: 76 papers with results

Page 1 of 2

Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A · The Journal of clinical endocrinology and metabolism · 2014
Randomized controlled trial · 10 results
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR · The lancet. Diabetes & endocrinology · 2014
Randomized controlled trial · 10 results
Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula: A Randomized Clinical Trial.
Tarvainen T · JAMA surgery · 2020
Randomized controlled trial · 5 results
Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study.
Chéreau E · PloS one · 2016
Randomized controlled trial · 3 results
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM · Drug design, development and therapy · 2015
Randomized controlled trial · 6 results
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
Ferolla P · The Lancet. Oncology · 2017
Randomized controlled trial · 11 results
Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC · Clinical journal of the American Society of Nephrology : CJASN · 2020
Randomized controlled trial · 5 results
Pasireotide does not improve efficacy of aspiration sclerotherapy in patients with large hepatic cysts, a randomized controlled trial.
Wijnands TFM · European radiology · 2018
Randomized controlled trial · 3 results
Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial.
Eaton AA · Annals of surgical oncology · 2016
Randomized controlled trial · 1 result
The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial.
Ma LW · Annals of surgery · 2017
Randomized controlled trial · 1 result
Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study.
Lacroix A · Pituitary · 2020
Randomized controlled trial · 5 results
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.
Henry RR · The Journal of clinical endocrinology and metabolism · 2013
Randomized controlled trial · 11 results
Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study.
Benamouzig R · Therapeutic advances in gastroenterology · 2018
Randomized controlled trial · 5 results
A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome.
Deloose E · Neurogastroenterology and motility · 2014
Randomized controlled trial · 7 results
Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: a Single‐Center, Phase I, Randomized, Four‐Way Crossover Study.
Breitschaft A · Journal of clinical pharmacology · 2014
Randomized controlled trial · 5 results
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
Beglinger C · Endocrine · 2012
Randomized controlled trial · 20 results
Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide.
Johnsson M · Endocrine · 2024
Randomized controlled trial · 9 results
Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs.
Gadelha M · Frontiers in endocrinology · 2019
Non-randomized trial · 3 results
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD · BMC endocrine disorders · 2016
Non-randomized trial · 14 results
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
Ramalingam S · PloS one · 2021
Non-randomized trial · 6 results
Safety and efficacy of pasireotide in dumping syndrome-results from a phase 2, multicentre study.
Tack J · Alimentary pharmacology & therapeutics · 2018
Non-randomized trial · 12 results
Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.
Tahara S · Endocrine journal · 2017
Non-randomized trial · 16 results
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M · The Journal of clinical endocrinology and metabolism · 2009
Non-randomized trial · 6 results
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M · Endocrine-related cancer · 2015
Non-randomized trial · 9 results
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
Feelders RA · Frontiers in endocrinology · 2023
Non-randomized trial · 2 results
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
Faggiano A · Endocrine · 2018
Non-randomized trial · 4 results
Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.
Singh B · Breast cancer research : BCR · 2014
Non-randomized trial · 15 results
Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.
Feun LG · Journal of hepatocellular carcinoma · 2018
Non-randomized trial · 5 results
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
Newell-Price J · European journal of endocrinology · 2020
Non-randomized trial · 5 results
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Findling JW · Endocrine · 2016
Non-randomized trial · 8 results
Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.
Schmid HA · Endocrine · 2016
Non-randomized trial · 5 results
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly.
Gadelha MR · Endocrine connections · 2020
Non-randomized trial · 4 results
Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.
Feldt-Rasmussen U · Frontiers in endocrinology · 2024
Non-randomized trial · 8 results
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.
Colao A · European journal of endocrinology · 2020
Non-randomized trial · 6 results
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J · Pituitary · 2015
Non-randomized trial · 10 results
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Fleseriu M · Clinical endocrinology · 2019
Non-randomized trial · 11 results
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK · Endocrine-related cancer · 2012
Non-randomized trial · 8 results
Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.
Lacroix A · Journal of endocrinological investigation · 2020
Non-randomized trial · 6 results
Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
Chen X · Clinical therapeutics · 2014
Non-randomized trial · 19 results
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Wolin EM · Cancer chemotherapy and pharmacology · 2013
Non-randomized trial · 10 results
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S · Journal of clinical pharmacology · 2014
Non-randomized trial · 11 results
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Norden AD · Neurology · 2015
Non-randomized trial · 9 results
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Breitschaft A · Diabetes research and clinical practice · 2014
Non-randomized trial · 6 results
Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
Boscaro M · Pituitary · 2014
Non-randomized trial · 6 results
Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Petersenn S · Endocrine · 2017
Non-randomized trial · 12 results
The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.
Simeoli C · Journal of endocrinological investigation · 2020
Non-randomized trial · 12 results
Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
Dietrich H · European journal of endocrinology · 2012
Non-randomized trial · 10 results
Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.
Øhrstrøm CC · Diabetes, obesity & metabolism · 2019
Non-randomized trial · 11 results
A prospective longitudinal study of Pasireotide in Nelson's syndrome.
Daniel E · Pituitary · 2018
Non-randomized trial · 7 results
Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.
Trementino L · Pituitary · 2015
Non-randomized trial · 7 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Signifor Signifor LAR	27 Oct 2026	dailymed.nlm.nih.gov (opens in a new tab)
EU	EMA	Signifor	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Not listed as banned by WADA Pasireotide is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

154 safety results for Pasireotide.

Human evidence· 154

After partial pancreatectomy, one pasireotide patient versus 2 hydrocortisone patients died within 30 days.
Randomized controlled trialn = 126
Deaths within 30 days
1 patients
pasireotide group
Deaths within 30 days
2 patients
hydrocortisone group
In mastectomy and axillary dissection patients, overall safety was comparable between pasireotide and placebo.
Randomized controlled trialn = 90
In severe polycystic liver disease, hyperglycemia occurred in 26/33 (79%) pasireotide recipients versus 4/15 (27%) placebo recipients (P<0.001).
Randomized controlled trialn = 48
Patients with hyperglycemia
26 patients
pasireotide LAR group, of 33
Proportion with hyperglycemia
79%
pasireotide LAR group
Patients with hyperglycemia
4 patients
placebo group, of 15
2 more measurements in the study.
In acromegaly, hyperglycemia-related events occurred in 57.3% with pasireotide LAR versus 21.7% with octreotide LAR.
Randomized controlled trialn not reported
Hyperglycemia-related adverse event rate
21.7%
octreotide LAR
Hyperglycemia-related adverse event rate
57.3%
pasireotide LAR
In uncontrolled acromegaly, hyperglycaemia occurred in 21 (33%) with pasireotide 40 mg versus nine (14%) with active control.
Randomized controlled trialn not reported
Hyperglycaemia
21 patients
pasireotide 40 mg
Hyperglycaemia
33%
pasireotide 40 mg
Hyperglycaemia
9 patients
active control
1 more measurement in the study.
In refractory carcinoid tumors, drug-related hyperglycemia occurred in 28.3% with pasireotide versus 5.3% with octreotide.
Randomized controlled trialn not reported
Drug-related hyperglycemia
28.3%
pasireotide LAR
Drug-related hyperglycemia
5.3%
octreotide LAR
In healthy volunteers, pasireotide 600 µg bid produced maximum mean ΔΔQTcI of 13.2 milliseconds (90% CI 11.4, 15.0) at 2 hours post-dose.
Randomized controlled trialn not reported
Mean placebo-subtracted ΔQTcI (ΔΔQTcI)
13.2 milliseconds
pasireotide 600 µg bid, maximum at 2 hours post-dose
90% CI of mean ΔΔQTcI
11.4 to 15 milliseconds
pasireotide 600 µg bid
In healthy men, pasireotide 600 μg sc was associated with higher preprandial glucose than placebo.
Randomized controlled trialn not reported

The top 24 of 154 results.

Doses studied · 77

The doses that these studies used. They are not recommendations.

40 mg/28 days, with optional titration to 60 mg at months 3 and 7Human
Species
human
Route
Not reported
Duration
12 months
Design
Randomized controlled trial · n = 358
40 mg every 28 daysHuman
Species
human
Route
Not reported
Duration
24 weeks
Design
Randomized controlled trial · n = 133
60 mg every 28 daysHuman
Species
human
Route
Not reported
Duration
24 weeks
Design
Randomized controlled trial · n = 133
900 μg twice a dayHuman
Species
human
Route
subcutaneous
Duration
7 days
Design
Randomized controlled trial · n = 126
60 mg, one injectionHuman
Species
human
Route
intramuscular
Duration
single injection 7 to 10 days before surgery
Design
Randomized controlled trial · n = 90
60 mg every 28 daysHuman
Species
human
Route
Not reported
Duration
Not reported
Design
Randomized controlled trial · n = 88

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
40 mg/28 days, with optional titration to 60 mg at months 3 and 7	Human	human	Not reported	12 months	Randomized controlled trial · n = 358
40 mg every 28 days	Human	human	Not reported	24 weeks	Randomized controlled trial · n = 133
60 mg every 28 days	Human	human	Not reported	24 weeks	Randomized controlled trial · n = 133
900 μg twice a day	Human	human	subcutaneous	7 days	Randomized controlled trial · n = 126
60 mg, one injection	Human	human	intramuscular	single injection 7 to 10 days before surgery	Randomized controlled trial · n = 90
60 mg every 28 days	Human	human	Not reported	Not reported	Randomized controlled trial · n = 88

6 of 77 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000159
Peptide version: 2
Peptide hash: f856e94f473eb388…
Data version: 308560

Latest changes

28 Oct 2026UpdatedData version 304197
27 Oct 2026CreatedData version 256753

For developers

curl -s https://pepbank.io/v1/briefs/pasireotide

Evidence summary for Pasireotide: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Adverse eventsWhole body	Human: 87 results from 38 studies: 11 increase, 2 decrease, 1 no significant change, 73 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	87
Glycemic controlMetabolic and weight	Human: 50 results from 19 studies: 21 increase, 14 decrease, 3 no significant change, 12 not reported. Strongest design: Randomized controlled trial	Animal: 6 results from 1 study: 4 increase, 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	56
PharmacokineticsPharmacology	Human: 48 results from 10 studies: 13 increase, 5 decrease, 3 mixed, 27 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	48
Tumor growthEndocrine and hormones	Human: 43 results from 14 studies: 9 increase, 7 decrease, 2 no significant change, 25 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 decrease. Strongest design: Animal study (in vivo)	Lab: 11 results from 5 studies: 1 increase, 6 decrease, 2 no significant change, 2 not reported. Strongest design: In vitro (cells)	No results	56
Gastrointestinal adverse eventsGastrointestinal	Human: 31 results from 16 studies: 5 increase, 26 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	31
Growth hormone and IGF-1Endocrine and hormones	Human: 29 results from 12 studies: 6 increase, 10 decrease, 13 not reported. Strongest design: Randomized controlled trial	No results	Lab: 6 results from 3 studies: 3 decrease, 2 no significant change, 1 mixed. Strongest design: In vitro (cells)	No results	35
Cortisol ControlEndocrine and hormones	Human: 26 results from 5 studies: 12 decrease, 14 not reported. Strongest design: Non-randomized trial	No results	No results	No results	26
Quality of lifeWhole body	Human: 15 results from 5 studies: 2 increase, 4 decrease, 1 no significant change, 8 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	15
Receptor activity and mechanismPharmacology	Human: 14 results from 5 studies: 1 increase, 9 decrease, 2 no significant change, 1 mixed, 1 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 1 increase, 1 decrease. Strongest design: Animal study (in vivo)	Lab: 51 results from 12 studies: 14 increase, 23 decrease, 9 no significant change, 1 mixed, 4 not reported. Strongest design: In vitro (cells)	No results	67
Disease controlWhole body	Human: 10 results from 3 studies: 1 decrease, 9 not reported. Strongest design: Non-randomized trial	No results	No results	No results	10
Endocrine ControlEndocrine and hormones	Human: 8 results from 2 studies: 5 decrease, 3 not reported. Strongest design: Non-randomized trial	No results	No results	No results	8
Heart functionCardiovascular	Human: 7 results from 3 studies: 2 increase, 5 decrease. Strongest design: Randomized controlled trial	No results	No results	No results	7

Outcome group	Human	Animal	Lab	Computer model	Total
Adverse eventsWhole body	Human: 87 results from 38 studies: 11 increase, 2 decrease, 1 no significant change, 73 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	87
Glycemic controlMetabolic and weight	Human: 50 results from 19 studies: 21 increase, 14 decrease, 3 no significant change, 12 not reported. Strongest design: Randomized controlled trial	Animal: 6 results from 1 study: 4 increase, 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	56
PharmacokineticsPharmacology	Human: 48 results from 10 studies: 13 increase, 5 decrease, 3 mixed, 27 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	48
Tumor growthEndocrine and hormones	Human: 43 results from 14 studies: 9 increase, 7 decrease, 2 no significant change, 25 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 decrease. Strongest design: Animal study (in vivo)	Lab: 11 results from 5 studies: 1 increase, 6 decrease, 2 no significant change, 2 not reported. Strongest design: In vitro (cells)	No results	56
Gastrointestinal adverse eventsGastrointestinal	Human: 31 results from 16 studies: 5 increase, 26 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	31
Growth hormone and IGF-1Endocrine and hormones	Human: 29 results from 12 studies: 6 increase, 10 decrease, 13 not reported. Strongest design: Randomized controlled trial	No results	Lab: 6 results from 3 studies: 3 decrease, 2 no significant change, 1 mixed. Strongest design: In vitro (cells)	No results	35
Cortisol ControlEndocrine and hormones	Human: 26 results from 5 studies: 12 decrease, 14 not reported. Strongest design: Non-randomized trial	No results	No results	No results	26
Quality of lifeWhole body	Human: 15 results from 5 studies: 2 increase, 4 decrease, 1 no significant change, 8 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	15
Receptor activity and mechanismPharmacology	Human: 14 results from 5 studies: 1 increase, 9 decrease, 2 no significant change, 1 mixed, 1 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 1 increase, 1 decrease. Strongest design: Animal study (in vivo)	Lab: 51 results from 12 studies: 14 increase, 23 decrease, 9 no significant change, 1 mixed, 4 not reported. Strongest design: In vitro (cells)	No results	67
Disease controlWhole body	Human: 10 results from 3 studies: 1 decrease, 9 not reported. Strongest design: Non-randomized trial	No results	No results	No results	10
Endocrine ControlEndocrine and hormones	Human: 8 results from 2 studies: 5 decrease, 3 not reported. Strongest design: Non-randomized trial	No results	No results	No results	8
Heart functionCardiovascular	Human: 7 results from 3 studies: 2 increase, 5 decrease. Strongest design: Randomized controlled trial	No results	No results	No results	7